ABSI
Absci Corporation
There isn't enough reported data to score ABSI yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ABSI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
ABSI's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABSI PE Valuation
ABSI has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ABSI Forward outlook
There aren't enough analyst estimates for ABSI to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ABSI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.78 | +$0.13 |
| Q2 2026 | -$0.79 | +$0.16 |
| Q1 2026 | -$0.82 | +$0.11 |
| Q4 2025 | -$0.84 | +$0.10 |
| Q3 2025 | -$0.91 | +$0.02 |
| Q2 2025 | -$0.95 | -$0.02 |
| Q1 2025 | -$0.93 | +$0.23 |
| Q4 2024 | -$0.94 | +$0.26 |
ABSI is still losing money, but far less than before: $0.78 per share over the past year, against $2.89 at its worst in late 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ABSI on earnings quality, reporting a profit while its opponent remains loss making.
ABSI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $304K | -20% |
| Q2 2026 | $318K | -46% |
| Q1 2026 | $215K | -82% |
| Q4 2025 | $650K | -2.3% |
| Q3 2025 | $378K | -78% |
| Q2 2025 | $593K | -53% |
| Q1 2025 | $1.2M | +31% |
| Q4 2024 | $665K | +97% |
ABSI's revenue has slid since its 2023 peak: $304,000 last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11511% | -3534 points |
| Q2 2026 | -10742% | -5448 points |
| Q1 2026 | -14347% | -11995 points |
| Q4 2025 | -4776% | -298 points |
| Q3 2025 | -7977% | -6279 points |
| Q2 2025 | -5294% | -3190 points |
| Q1 2025 | -2352% | +265 points |
| Q4 2024 | -4477% | +2842 points |
ABSI's operating margin was −11511% last quarter, down 3534 points from the same quarter a year ago, near the bottom of its range since 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ABSI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ABSI on profitability, with a higher operating margin.
ABSI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$29.5M | -$3.5M |
| Q2 2026 | -$27.6M | -$10.5M |
| Q1 2026 | -$26.3M | -$4.5M |
| Q4 2025 | -$29.1M | -$12.1M |
| Q3 2025 | -$26M | -$5.2M |
| Q2 2025 | -$17.1M | +$80K |
| Q1 2025 | -$21.9M | -$4M |
| Q4 2024 | -$17M | -$2M |
ABSI has burned cash in almost every quarter: −$112M over the past year, against −$82M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ABSI on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABSI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +14.3M shares |
| 1 year | +19% | +28M shares |
| 3 years | +86% | +79.6M shares |
| 5 years | +874% | +154M shares |
| Available history | +90% | +81.4M shares |
ABSI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ABSI Net Leverage
ABSI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ABSI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 52.6 | Neutral |
ABSI's weekly RSI is 53 (neutral) and its Stochastic is 53 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ABSI PE vs Healthcare Sector
ABSI has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ABSI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.85 | 7.3% below |
| 20 week MA | $9.39 | 2.8% below |
| 50 week MA | $6.24 | 46% above |
| 100 week MA | $4.70 | 94% above |
| 200 week MA | $3.87 | 136% above |
ABSI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 136% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ABSI on trend strength, trading above more of its moving averages.
ABSI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $22.9 | $8.67 | -62% |
| 2022 | $8.67 | $2.17 | -75% |
| 2023 | $2.17 | $4.20 | +94% |
| 2024 | $4.20 | $2.77 | -34% |
| 2025 | $2.77 | $3.57 | +29% |
| 2026 YTD | $3.57 | $9.13 | +156% |
ABSI has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.